BioAge Shares Rise on Positive Trial Data

Dow Jones

Apr 21

By Katherine Hamilton

Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation.

The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year.

In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk.

Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said.

Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 21, 2026 07:58 ET (11:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2629303660"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629303660\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629303660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629303660","market":"other","top_or_hot":-1,"title":"BioAge Shares Rise on Positive Trial Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs</a> were higher after the company shared positive data for a trial of its drug as a treatment for inflammation. \n</p>\n<p>\n  The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year. \n</p>\n<p>\n  In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk. \n</p>\n<p>\n  Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said. \n</p>\n<p>\n  Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 07:58 ET (11:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Shares Rise on Positive Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Shares Rise on Positive Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 19:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/BIOA\">BioAge Labs</a> were higher after the company shared positive data for a trial of its drug as a treatment for inflammation. \n</p>\n<p>\n  The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year. \n</p>\n<p>\n  In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk. \n</p>\n<p>\n  Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said. \n</p>\n<p>\n  Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2026 07:58 ET (11:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629303660","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629303660","pubTimestamp":1776772680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation.The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year.In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk.Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said.Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BIOA":"BioAge Labs Inc."},"translate_title":"BioAge股价因积极的试验数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation. \n\n\n  The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year. \n\n\n  In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk. \n\n\n  Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said. \n\n\n  Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2026 07:58 ET (11:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}